Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

The Disposition of Gemifloxacin, a New Fluoroquinolone Antibiotic, in Rats and Dogs

J. V. Ramji, N. E. Austin, G. W. Boyle, M. H. Chalker, G. Duncan, A. J. Fairless, F. J. Hollis, D. F. McDonnell, T. J. Musick and P. C. Shardlow
Drug Metabolism and Disposition April 2001, 29 (4) 435-442;
J. V. Ramji
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
N. E. Austin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. W. Boyle
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. H. Chalker
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. Duncan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. J. Fairless
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
F. J. Hollis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. F. McDonnell
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
T. J. Musick
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. C. Shardlow
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Gemifloxacin is a fluoroquinolone antibacterial compound with enhanced affinity for bacterial topoisomerase IV and is being developed for the treatment of respiratory and urinary tract infections. The disposition and metabolic fate of this antibiotic was studied in the rat and the dog, the animal species used in its toxicological evaluation. The investigations were carried out following oral and intravenous administration of gemifloxacin mesylate. Gemifloxacin is a racemic compound; therefore, the pharmacokinetics of its individual (+) and (−) enantiomers were characterized using a chiral high-performance liquid chromatography/tandem mass spectrometry assay. In both rat and dog, the pharmacokinetic profiles of the (+) and (−) enantiomers were essentially identical. The enantiomers were rapidly absorbed following oral administration of racemic gemifloxacin mesylate. They distributed rapidly beyond total body water, and their blood clearance values were approximately equal to one quarter of the hepatic blood flow in each species. Terminal phase elimination half-lives were ca. 2 h in the rat and 5 h in the dog. Gemifloxacin was metabolized to a limited extent following oral and intravenous administration of [14C]gemifloxacin mesylate, and all metabolites formed were relatively minor. The principal metabolites formed were the E-isomer (4–6% of dose) and the acyl glucuronide of gemifloxacin (2–6% of dose) in both species andN-acetyl gemifloxacin (2–5% of dose) in the rat. Data obtained following intravenous administration indicated that gemifloxacin-related material is eliminated from the body via urinary excretion, biliary secretion, and gastrointestinal secretion. Material was eliminated approximately equally by the three routes in the dog, whereas a slightly higher proportion of the dose was eliminated in the urine (46%) and a lower proportion in the bile (12%) of rats.

Footnotes

  • Send reprint requests to: Mr. Jay V. Ramji, Drug Metabolism and Pharmacokinetics, SmithKline Beecham Pharmaceuticals, The Frythe, Welwyn, Hertfordshire, AL6 9AR, UK. E-mail:Jayant_Ramji{at}sbphrd.com

  • Abbreviations used are::
    SB
    SmithKline Beecham
    HPLC
    high-pressure liquid chromatography
    LSC
    liquid scintillation counting
    MS
    mass spectrometry
    fb
    free base
    G.I. tract
    gastrointestinal tract
    AUC(0–t) area under the plasma concentration-time curve to the last quantifiable data point
    AUC(t–inf), area under the plasma concentration-time curve from the last quantifiable data point to infinity
    AUC(0–inf)
    area under the plasma concentration-time curve to infinity
    AUMC(0–inf)
    area under the moment curve to infinity
    Vss
    volume of distribution at steady state
    • Received September 22, 2000.
    • Accepted December 20, 2000.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 29 (4)
Drug Metabolism and Disposition
Vol. 29, Issue 4
1 Apr 2001
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
The Disposition of Gemifloxacin, a New Fluoroquinolone Antibiotic, in Rats and Dogs
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

The Disposition of Gemifloxacin, a New Fluoroquinolone Antibiotic, in Rats and Dogs

J. V. Ramji, N. E. Austin, G. W. Boyle, M. H. Chalker, G. Duncan, A. J. Fairless, F. J. Hollis, D. F. McDonnell, T. J. Musick and P. C. Shardlow
Drug Metabolism and Disposition April 1, 2001, 29 (4) 435-442;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

The Disposition of Gemifloxacin, a New Fluoroquinolone Antibiotic, in Rats and Dogs

J. V. Ramji, N. E. Austin, G. W. Boyle, M. H. Chalker, G. Duncan, A. J. Fairless, F. J. Hollis, D. F. McDonnell, T. J. Musick and P. C. Shardlow
Drug Metabolism and Disposition April 1, 2001, 29 (4) 435-442;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Metabolic enzymes in nintedanib metabolism
  • Mechanism of AO Inactivation by Hydralazine
  • Warfarin PBPK modeling with target binding
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics